Anzeige
Mehr »
Login
Donnerstag, 09.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Vor Neubewertung: Kupfer-Geheimtipp veröffentlich in dieser Sekunde sensationelle Bohrergebnisse
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JLMD | ISIN: US03168L1052 | Ticker-Symbol: 2DT
Tradegate
07.05.24
14:32 Uhr
6,250 Euro
+0,100
+1,63 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AMNEAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMNEAL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,0506,20008.05.
6,0506,20008.05.

Aktuelle News zur AMNEAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAmneal Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
MoAssessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts1
MoAmneal agrees to $272.5M settlement to resolve opioid lawsuits1
FrEarnings call: Amneal Pharmaceuticals sees robust growth in Q1 20241
FrAmneal stock climbs on Q1 report, opioid settlement update1
FrGeneric Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement1
FrAmneal Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary1
FrAmneal shares up nearly 4% on better-than-expected Q1 results1
FrAmneal Pharmaceuticals, Inc. Q1 Earnings Summary2
FrAmneal Pharmaceuticals, Inc. - 8-K, Current Report1
FrAmneal Pharmaceuticals Non-GAAP EPS of $0.14 beats by $0.05, revenue of $659M beats by $39.97M1
FrAmneal Reports First Quarter 2024 Financial Results55BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") announced its results today for the first quarter ended March 31, 2024. "We are extremely...
► Artikel lesen
02.05.Amneal Pharmaceuticals Q1 2024 Earnings Preview-
24.04.FDA approves Amneal's generic version of OTC Narcan2
24.04.Amneal's OTC Naloxone Nasal Spray Receives FDA Approval For Opioid Overdose Emergency Treatment2
08.04.Bausch Health drops after suing Amneal Pharma over Xifaxan generic4
08.04.Bausch Health (BHC) Starts Litigation Against Amneal for Xifaxan6
06.04.Bausch Health sues Amneal Pharma over Xifaxan generic4
06.04.Bausch Health Companies Inc: Bausch Health sues Amneal over Xifaxan patent rights3
06.04.Bausch Health Companies Inc.: Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals481LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today...
► Artikel lesen
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1